Body

Drug combination shows promise for newly diagnosed blood cancer patients, study finds

ANN ARBOR, Mich. — A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients, according to a study led by the University of Michigan Comprehensive Cancer Center.

The drug combination includes a novel proteasome inhibitor called carfilzomib, combined with lenalidomide and low-dose dexamethasone. This is the first study to look at carfilzomib as a front-line treatment of patients with myeloma, a type of cancer that arises in the plasma cells.

University of Hawaii at Manoa research focuses on congenital abnormality

University of Hawaii at Manoa research focuses on congenital abnormality

Researchers at the University of Hawai'i at Mānoa have developed innovative techniques that could have profound effects on congenital cervical vertebrae malformation research.

Aromatase inhibitors increased risk of heart disease in postmenopausal women with breast cancer

SAN ANTONIO — Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased risk for developing cardiovascular disease, according to the results of a meta-analysis.

These data, presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, indicate that women presenting with breast cancer treatment who have risk factors for cardiovascular disease should be considered for a shorter duration of use of aromatase inhibitors.

Obese women with ER-positive/HER2-negative breast cancer have poorer survival rates

SAN ANTONIO — Obesity was associated with worse overall and disease-free survival in women with operable breast cancer treated with adjuvant chemotherapy, but for the first time, researchers observed this finding in only a specific subset of patients – those with estrogen receptor (ER)-positive/HER2-negative disease.

About one third of all adults in the United States are obese, posing a major public health problem because of obesity's association with an increased risk of diabetes and heart disease. This study indentified a new hazard associated with obesity.

Most women do not get recommended mammograms

SAN ANTONIO — Only half of eligible women in the United States are getting their annual mammograms, even if they have insurance to pay for the procedure, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.

Identifying lung cancer gene markers shows promise in identifying patients needing chemo

Cancer researchers have identified six gene markers present in early stage non-small cell lung cancer (NSCLC) that show promise in helping oncologists better identify which tumors will relapse after curative surgery, according to a study presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago.

Exposure to North Dakota road material may increase risk of lung cancer

New data shows that people exposed to the mineral erionite found in the gravel of road materials in North Dakota may be at significantly increased risk of developing mesothelioma, a type of lung cancer most often associated with asbestos exposure, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago.

Personalized molecular therapy shows promising results for people with advanced lung cancer

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago.

Adding ipilimumab to standard chemotherapy treatment for late-stage lung cancer may improve survival

– Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago.

Non-invasive SRT as good as surgery for elderly patients with early lung cancer

A new study shows that a new type of targeted radiation therapy called stereotactic radiation therapy is just as good as surgery for patients aged 75 and older with early-stage lung cancer, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago.

Weekend and public holiday admissions increased the risk of hospital deaths by up to 41 percent

Patients treated by Welsh (UK) hospitals for upper gastrointestinal (GI) bleeding were 41% more likely die if they were admitted on a public holiday and 13% more likely if it was at the weekend, according to research in the January issue of Alimentary Pharmacology and Therapeutics.

Researchers who analysed the records of 22,299 people admitted a total of 24,421 times between 1999 and 2007 also found that admissions, but not death rates, were significantly influenced by social deprivation.

Estrogen alone is effective for reducing breast cancer risk

SAN ANTONIO — While endogenous estrogen (i.e., estrogen produced by ovaries and by other tissues) does have a well-known carcinogenic impact, hormone replacement therapy (HRT) utilizing estrogen alone (the exogenous estrogen) provides a protective effect in reducing breast cancer risk, according to study results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

Blue whale-sized mouthfuls make foraging super efficient

Diving blue whales can dive for anything up to 15 minutes. However, Bob Shadwick from the University of British Columbia, Canada, explains that blue whales may be able to dive for longer, because of the colossal oxygen supplies they could carry in their blood and muscles, so why don't they? 'The theory was that what they are doing under water must use a lot of energy,' says Shadwick.

La Jolla Institute validates Type 1 diabetes computer model's predictive success through lab testing

SAN DIEGO – (December 9, 2010) – A La Jolla Institute team, led by leading type 1 diabetes researcher Matthias von Herrath, M.D., has demonstrated the effectiveness of a recently developed computer model in predicting key information about nasal insulin treatment regimens in type 1 (juvenile) diabetes. Development of the software, the Type 1 Diabetes PhysioLab® Platform, was funded through the peer-reviewed grant program of the American Diabetes Association.

Weightlifting does not appear to increase risk of arm swelling for breast cancer survivors

A slowly progressive weight lifting program for breast cancer survivors did not increase their risk of lymphedema (arm swelling and discomfort), according to a study that will appear in the December 22/29 issue of JAMA. The study is being released early online to coincide with its presentation at the San Antonio Breast Cancer Symposium.